The pharmaceutical manufacturer CLS Behring is investing approx. 362 million euros in the new production building on the Görzhäuser Hof in Marburg. With this production building, the capacity is increased fourfold. There arise 20 different drugs for patients with blood clotting disorders. Production is scheduled to start there at the end of 2022.
Source: CLS Behring News, 26.03.2018, JBG Research
